Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer

Zachary A P Wintrob, Jeffrey P. Hammel, George K. Nimako, Dan P. Gaile, Alan Forrest, Alice C. Ceacareanu

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

GM-CSF and G-CSF are widely used for their benefit in reducing chemotherapy-associated neutropenia. However, whether GM- or G-CSF administration could have tumorigenic or pro-metastatic effects or whether insulin resistance could negatively impact such effects is not known. Their ability to stimulate monocyte production at the same time with the highly sought after neutrophils’ production, enables an enhanced potential for activation of tumor-associated macrophages. At the same time, IL-7 remains the main driver of B and T cell differentiation and maturation, a process linked to the development of insulin resistance and response to diabetes pharmacotherapy. Insulin secretagogues have the potential to interfere with the hematopoiesis process, respectively with the formation of lineages that may lead to a tumorigenic or pro-metastatic phenotype, but this relationship has not been yet investigated. The data presented here shows the relationship between pre-existing use of insulin secretagogues in women diagnosed with breast cancer and type 2 diabetes mellitus, the GM-CSF, G-CSF and IL-7 cytokine profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis evaluating the relationship between investigated cytokines stratified by secretagogue use and controls, and interferon is also provided.

LanguageEnglish (US)
Pages277-283
Number of pages7
JournalData in Brief
Volume11
DOIs
StatePublished - Apr 1 2017

Fingerprint

incident
cancer
chronic illness
activation
driver
ability
time

Keywords

  • Breast cancer
  • Cancer outcomes
  • Cancer prognosis
  • Diabetes
  • G-CSF
  • GM-CSF
  • Hematopoiesis
  • Hematopoietic cytokines
  • IL-7
  • Secretagogue

ASJC Scopus subject areas

  • Education
  • General

Cite this

Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer. / Wintrob, Zachary A P; Hammel, Jeffrey P.; Nimako, George K.; Gaile, Dan P.; Forrest, Alan; Ceacareanu, Alice C.

In: Data in Brief, Vol. 11, 01.04.2017, p. 277-283.

Research output: Contribution to journalArticle

Wintrob, Zachary A P ; Hammel, Jeffrey P. ; Nimako, George K. ; Gaile, Dan P. ; Forrest, Alan ; Ceacareanu, Alice C./ Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer. In: Data in Brief. 2017 ; Vol. 11. pp. 277-283
@article{9b707fee15b94f23a5c0a4574caa5319,
title = "Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer",
abstract = "GM-CSF and G-CSF are widely used for their benefit in reducing chemotherapy-associated neutropenia. However, whether GM- or G-CSF administration could have tumorigenic or pro-metastatic effects or whether insulin resistance could negatively impact such effects is not known. Their ability to stimulate monocyte production at the same time with the highly sought after neutrophils’ production, enables an enhanced potential for activation of tumor-associated macrophages. At the same time, IL-7 remains the main driver of B and T cell differentiation and maturation, a process linked to the development of insulin resistance and response to diabetes pharmacotherapy. Insulin secretagogues have the potential to interfere with the hematopoiesis process, respectively with the formation of lineages that may lead to a tumorigenic or pro-metastatic phenotype, but this relationship has not been yet investigated. The data presented here shows the relationship between pre-existing use of insulin secretagogues in women diagnosed with breast cancer and type 2 diabetes mellitus, the GM-CSF, G-CSF and IL-7 cytokine profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis evaluating the relationship between investigated cytokines stratified by secretagogue use and controls, and interferon is also provided.",
keywords = "Breast cancer, Cancer outcomes, Cancer prognosis, Diabetes, G-CSF, GM-CSF, Hematopoiesis, Hematopoietic cytokines, IL-7, Secretagogue",
author = "Wintrob, {Zachary A P} and Hammel, {Jeffrey P.} and Nimako, {George K.} and Gaile, {Dan P.} and Alan Forrest and Ceacareanu, {Alice C.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.dib.2017.02.027",
language = "English (US)",
volume = "11",
pages = "277--283",
journal = "Data in Brief",
issn = "2352-3409",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer

AU - Wintrob,Zachary A P

AU - Hammel,Jeffrey P.

AU - Nimako,George K.

AU - Gaile,Dan P.

AU - Forrest,Alan

AU - Ceacareanu,Alice C.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - GM-CSF and G-CSF are widely used for their benefit in reducing chemotherapy-associated neutropenia. However, whether GM- or G-CSF administration could have tumorigenic or pro-metastatic effects or whether insulin resistance could negatively impact such effects is not known. Their ability to stimulate monocyte production at the same time with the highly sought after neutrophils’ production, enables an enhanced potential for activation of tumor-associated macrophages. At the same time, IL-7 remains the main driver of B and T cell differentiation and maturation, a process linked to the development of insulin resistance and response to diabetes pharmacotherapy. Insulin secretagogues have the potential to interfere with the hematopoiesis process, respectively with the formation of lineages that may lead to a tumorigenic or pro-metastatic phenotype, but this relationship has not been yet investigated. The data presented here shows the relationship between pre-existing use of insulin secretagogues in women diagnosed with breast cancer and type 2 diabetes mellitus, the GM-CSF, G-CSF and IL-7 cytokine profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis evaluating the relationship between investigated cytokines stratified by secretagogue use and controls, and interferon is also provided.

AB - GM-CSF and G-CSF are widely used for their benefit in reducing chemotherapy-associated neutropenia. However, whether GM- or G-CSF administration could have tumorigenic or pro-metastatic effects or whether insulin resistance could negatively impact such effects is not known. Their ability to stimulate monocyte production at the same time with the highly sought after neutrophils’ production, enables an enhanced potential for activation of tumor-associated macrophages. At the same time, IL-7 remains the main driver of B and T cell differentiation and maturation, a process linked to the development of insulin resistance and response to diabetes pharmacotherapy. Insulin secretagogues have the potential to interfere with the hematopoiesis process, respectively with the formation of lineages that may lead to a tumorigenic or pro-metastatic phenotype, but this relationship has not been yet investigated. The data presented here shows the relationship between pre-existing use of insulin secretagogues in women diagnosed with breast cancer and type 2 diabetes mellitus, the GM-CSF, G-CSF and IL-7 cytokine profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis evaluating the relationship between investigated cytokines stratified by secretagogue use and controls, and interferon is also provided.

KW - Breast cancer

KW - Cancer outcomes

KW - Cancer prognosis

KW - Diabetes

KW - G-CSF

KW - GM-CSF

KW - Hematopoiesis

KW - Hematopoietic cytokines

KW - IL-7

KW - Secretagogue

UR - http://www.scopus.com/inward/record.url?scp=85013486040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013486040&partnerID=8YFLogxK

U2 - 10.1016/j.dib.2017.02.027

DO - 10.1016/j.dib.2017.02.027

M3 - Article

VL - 11

SP - 277

EP - 283

JO - Data in Brief

T2 - Data in Brief

JF - Data in Brief

SN - 2352-3409

ER -